Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668172 | 0.86 | LMNA (0.38) | LMNAPRKDCALDH1A3ERN1ALDH1A1 | |
| SCHEMBL30634089 | 0.78 | LMNA (0.40) | LMNAPRKDCALDH1A3ERN1ALDH1A1 | |
| SCHEMBL21047975 | 0.78 | LMNA (0.40) | LMNAPRKDCALDH1A3ERN1ALDH1A1 | |
| SCHEMBL5883309 | 0.78 | ERN1 (0.58) | LMNAPRKDCERN1MAPT | |
| SCHEMBL2919357 | 0.75 | PTGS2 (0.48) | LMNAPRKDCERN1ALDH1A1MAPT | |
| SCHEMBL12135681 | 0.75 | ERN1 (0.48) | LMNAPRKDCERN1ALDH1A1MAPT | |
| SCHEMBL332788 | 0.74 | ERN1 (0.47) | LMNAPRKDCERN1ALDH1A1 | |
| SCHEMBL29945684 | 0.74 | ERN1 (0.47) | LMNAPRKDCERN1ALDH1A1 | |
| SCHEMBL1592418 | 0.74 | ERN1 (0.57) | LMNAPRKDCERN1ALDH1A1MAPT | |
| SCHEMBL31353147 | 0.74 | LMNA (0.41) | LMNAPRKDCALDH1A3ERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023214325-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS | NOVARTIS AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| US-7576098-B2 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1828152-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | BRISTOL MYERS SQUIBB CO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1828152-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | Bristol-Myers Squibb Company (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| WO-2006062972-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | TFPI, F7, HABP2 | LMNA 729/4885PRKDC 1129/4885ALDH1A3 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.